PSNL News and Press, Personalis Inc. From 01/11/21

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2020. Personalis estimates revenue of approximately $20.2 million for the fourth ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time. About Personalis, Inc. Personalis, Inc. is a...

Personalis ([[PSNL]] +2.9%) announces the launch of its proprietary Neoantigen Presentation Score (‘NEOPS’).NEOPS combines the tumor genomic and immune-related analytics of the Personalis® NeXT Platform™ to create a composite biomarker. NEOPS leverages Personalis...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its proprietary Neoantigen Presentation Score (NEOPS). NEOPS combines analysis from Personalis’ state-of-the-art tumor neoantigen prediction tool, SHERPA™, with mechani...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of its Systematic HLA Epitope Ranking Pan Algorithm (SHERPA), the company’s proprietary, machine learning-based tool for the comprehensive identification and characterization of ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis h...

Despite Covid-19, Personalis has seen a big jump in its share price while underlying achievements are held back by the virus. I liked the appeal of the business and anecdotal improvements earlier this year (orders) as current numbers do not reflect the real progress being made. Af...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia. The company will ...

Multiple companies are working on next-gen blood biopsies tech to detect cancer. The potential market size is big according to most estimates and analysts. Mergers and acquisitions seem to suggest that the era of liquid biopsies has arrived. The frontrunners highlighted in the...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT Dx TM - at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled “An exome and transc...